A randomized controlled trial comparing the effects of dapagliflozin and DPP-4 inhibitors on glucose variability and metabolic parameters in patients with type 2 diabetes mellitus on insulin

BACKGROUND: Dipeptidyl peptidase-4 (DPP-4) inhibitors and sodium–glucose co-transporter 2 (SGLT2) inhibitors improve hyperglycemia, and the usefulness of co-administration of DPP-4 inhibitors and insulin therapy has been well established. However, it has been still uncertain whether combination ther...

Descripción completa

Detalles Bibliográficos
Autores principales: Nomoto, Hiroshi, Miyoshi, Hideaki, Sugawara, Hajime, Ono, Kota, Yanagiya, Shingo, Oita, Mayuko, Nakamura, Akinobu, Atsumi, Tatsuya
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2017
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514514/
https://www.ncbi.nlm.nih.gov/pubmed/28725273
http://dx.doi.org/10.1186/s13098-017-0255-8

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5514514/
https://www.ncbi.nlm.nih.gov/pubmed/28725273
http://dx.doi.org/10.1186/s13098-017-0255-8

Ejemplares similares